#CandidaAuris #SuperBugFungus youtu.be/s_x-o2llxps?...

A phased approach to implementation of a Candida auris screening program in a large, acute care hospital system A phased Candida auris screening program was implemented in a large acute care hospital system. This program used high-risk criteria as outlined by the Centers for Disease Control and Prevention to su...

A phased Candida auris screening program improved early detection and kept positivity rates low 🧫✨ Powered by strong collaboration and continuous quality improvement.
🔗 www.ajicjournal.org/article/S019...

#InfectionPrevention #CandidaAuris #IPAC

Dangerous, drug-resistant fungus spreads across N.Y., N.J. hospitals and nursing homes A potentially deadly and drug-resistant fungus is spreading nationwide, including New York and New Jersey.

With Candida auris spreading through hospitals and nursing homes across the country, staying ahead is critical. PraediAlert identifies these infections and sends immediate alerts, ensuring IPs can respond quickly.

www.cbsnews.com/newyork/news...

#candidaauris #PraediAlert

Eindelijk weten we waarom Candida auris levensgevaarlijk is Hij dook in 2009 schijnbaar uit het niets op, maar ontwikkelt zich razendsnel tot een dodelijke bedreiging die wereldwijd optreedt. We hebben het over de…

Dodelijk mechanisme ontdekt www.foodlog.nl/artikel/eind... #gezondheid #schimmels #candidaauris #schimmelresistentie #aspergillusfumigatus

Superbug hits 28 states, including Alabama: Where the deadly fungus is spreading A superbug that’s resistant to antibiotics is quickly spreading through the United States.

This is the last thing I need to hear about right now when I’m dealing with mold sickness. 😮‍💨🦠😩

‘Superbug hits 28 states, including Alabama: Where the deadly fungus is spreading’
www.al.com/news/2025/12...
#Candidaauris #Superbug
#ClimateCrisis #Climate

Why Candida auris Is Hard to Control (And What It Means) Candida auris is hard to control because it colonizes human skin without symptoms, persists for weeks on hospital surfaces and equipment, resists multiple antifungal drug classes, and is frequently misidentified by routine lab tests. These features enable silent spread in healthcare facilities, delayed effective therapy, and outbreaks that are difficult to stop. Containment requires targeted screening, strict infection prevention, reliable diagnostics, and careful use of limited antifungal options.

This stealthy fungus sticks to skin, lingers on surfaces, and shrugs off meds—no wonder outbreaks are tough to stop. What makes Candida auris different, and how can hospitals fight back? Have you seen new screening protocols? #AntifungalResistance #CandidaAuris #Diagnostics #HospitalInfections…

Killer fungus becoming more infectious and spreading worldwide Study says fungus uses proactive ways to evade drugs and human immune response

Happy new year?

👀 #CandidaAuris

www.independent.co.uk/news/science...

Hospitals, nursing homes and other medical facilities are struggling to gain ground on a drug-resistant and deadly fungus that has infected at least 7,000 people in 2025, according to tracking by the Centers for Disease Control and Prevention...thehill

#Candidaauris

Candida auris spreads globally as drug resistance and virulence increase, review finds Invasive fungal infections affect approximately 6.5 million people per year, with high mortality rates

#Candidaauris spreads globally as #drugresistance and virulence increase, review finds. Invasive #fungalinfections affect approximately 6.5 million people per year, with high #mortalityrates . . . rhinformatics.beehiiv.com/p/candida-au...

Candida auris skin tropism and antifungal resistance are mediated by carbonic anhydrase Nce103 - Nature Microbiology Candida auris can scavenge carbon dioxide from microenvironments through Nce103 to sustain fitness when colonizing human skin.

Out Now! Candida auris skin tropism and antifungal resistance are mediated by carbonic anhydrase Nce103 #CandidaAuris #AntifungalResistance #Microbiology

www.nature.com/articles/s41...

Candida auris, studio svela possibile tallone d'achille del fungo killer che spaventa ospedali (Adnkronos) - E' particolarmente pericoloso per le persone gravemente malate e per questo gli ospedali sono i luoghi in cui fa più danni. E' la Candida auris, finita negli anni alla ribalta delle cronache come 'fungo killer' perché, s...

TI POTREBBE INTERESSARE: Candida auris, studio svela possibile tallone d'achille del fungo killer che spaventa ospedali ... LEGGI TUTTO #CandidaAuris #FungoKiller #Salute #MalattieInfecciose #Ospedali

New findings on Candida auris Read more about potential targets for future therapies!

🧫 How does the multi-resistant #fungus #CandidaAuris become resistant to antifungal therapies?

A team involving #MedUniVienna identified new targets that could be used to curb the spread & infections caused by the fungus. ⬇️

📰 @natmicrobiol.nature.com​

Candida auris, studio svela possibile tallone d'achille del fungo killer che spaventa ospedali (Adnkronos) - E' particolarmente pericoloso per le persone gravemente malate e per questo gli ospedali sono i luoghi in cui fa più danni. E' la Candida auris, finita negli anni alla ribalta delle cronache come 'fungo killer' perché, s...

È ACCADUTO IERI: Candida auris, studio svela possibile tallone d'achille del fungo killer che spaventa ospedali ... LEGGI TUTTO #CandidaAuris #FungoKiller #Salute #Ospedali #Infezioni

Candida auris, studio svela possibile tallone d'achille del fungo killer che spaventa ospedali (Adnkronos) - E' particolarmente pericoloso per le persone gravemente malate e per questo gli ospedali sono i luoghi in cui fa più danni. E' la Candida auris, finita negli anni alla ribalta delle cronache come 'fungo killer' perché, s...

Candida auris, studio svela possibile tallone d'achille del fungo killer che spaventa ospedali ... LEGGI TUTTO #CandidaAuris #fungoKiller #salute #ospedali #malattie

👾 Candidozyma auris : vigilance en NA !
Le CPIAS NA recommande un dépistage systématique : passage en réa/USI <12 mois, antécédent de colonisation, contacts d’un cas.
🔍 Détecter tôt = éviter la diffusion.
ℹ️ urls.fr/6_Qz76
@ARS_NA @SantePubliqueFr
#CandidaAuris #IAS #Prévention

#ICYMI- the December issue of @JMDiagn is now live!

Full issue: https://www.jmdjournal.org/issue/S1525-1578(24)X0014-8

#NGS #bladdercancer #Candidaauris

Researchers discover all-new antifungal drug candidate in McMaster’s greenhouse A research team at McMaster University has discovered a new drug class that could someday lead to breakthrough treatments for dangerous fungal infections. The new molecules, dubbed coniotins, were isolated from a plant-dwelling fungus called Coniochaeta hoffmannii — the samples of which were collected from the McMaster greenhouse, located on the university’s campus. Detailed recently in the journal Nature Communications, the discovery responds to a critical need for new antifungal medicines. “There is a huge, growing clinical need for new drugs that target fungal infections,” says Gerry Wright, a professor of biochemistry and biomedical sciences at McMaster and principal investigator on the new study. “Unlike antibiotics, of which there are dozens of different classes approved for use in clinics, there are really only three classes of antifungals on the market right now.” The reason for such a limited arsenal, Wright says, is two-fold. First, although disease-causing fungi are microscopic like bacteria and viruses, they’re actually more closely related to humans than they are to other microbes — “so things that kill fungi tend to kill us too,” he says. This makes finding antifungals that are safe for human consumption a real challenge. And then there’s the historical lack of urgency. Wright says that most fungi cannot withstand our internal body temperature, and usually die off before they can cause serious infection. It’s why fungal infections typically occur on us instead of in us — think athlete’s foot, for example. Because our bodies can generally handle these pathogens naturally, Wright says there’s been little incentive for pharmaceutical companies to invest in antifungal R&D — until recently. “Discovery remains a challenge today, but the level of urgency has changed dramatically over the past 15 years or so,” he says. “In 2009, a novel fungal pathogen called Candida auris emerged all over the world, and this fungus thrives at higher temperatures — and it can be extremely drug-resistant, too.” C. auris is particularly problematic for individuals with compromised immune systems, like cancer patients undergoing chemotherapy. It can infect the lungs, the bloodstream, and the nervous system, and can be fatal. For these reasons, C. auris sits atop the World Health Organization’s list of priority fungal pathogens. It’s a good thing then that the Wright Lab’s new molecule exhibits potent activity against C. auris. Indeed, the research team showed that coniotins not only attack C. auris and several other fungal pathogens, but do so without harming human cells. The new molecules function unlike any other antifungal on the market. Where most target proteins and membranes, coniotins instead bind to the fungal cell wall. Wright, a member of the Michael G. DeGroote Institute for Infectious Disease Research at McMaster, likens the cell wall to the candy coating on an M&M — a protective shell that provides structural integrity for what’s inside. Disturbing this structure, as coniotins do, fundamentally changes how well the organism can survive. Xufei Chen, a postdoctoral fellow in Wright’s lab and first-author on the new paper, identified the new drug class through a process called prefractionation, which allows scientists to tease specific molecules out from complex chemical mixtures. “Since the golden age of antibiotic discovery, progress has slowed, due primarily to the frequent rediscovery of known compounds,” she says. “To address this, we implemented a prefractionation screening approach to target overlooked or masked metabolites. By integrating mass spectrometry, metabolomics, and computational analysis, I was able to discover this previously hidden molecule.” Using this same process, Wright’s lab recently discovered a new class of antibiotics. They have also used prefractionation to identify several other new drug candidates, which remain under study. “What’s really amazing is that we’ve only screened about five percent of the chemical library that we’ve built here at McMaster,” Wright says. “We have an immense, largely unexplored chemical space at our fingertips, and a cost-effective way to reduce the rediscovery of known compounds. Who knows what else is in there?” Wright’s team is eager to move coniotins along the development pathway. The next steps, he says, include producing it at scale through fermentation, and formulating the new drug class so that it may eventually be suitable intravenous (IV) delivery. Research Generative AI and the future of research writing: 2025 Hooker Distinguished Visiting Professor Lecture

Researchers discover a new antifungal drug candidate in their university's greenhouse

@gdwantibiotics.bsky.social

#AntifungalResistance #NaturalProducts #DrugDiscovery #CandidaAuris

Drug-resistant fungus Candidozyma auris confirmed to spread rapidly in European hospitals: ECDC calls for urgent action The latest survey from ECDC, the fourth of its kind, confirms that Candidozyma auris (formerly Candida auris) continues to spread quickly across European hospitals.

#Candidaauris is spreading fast in European hospitals, with rising cases, endemicity, and gaps in control, warns ECDC. This drug-resistant fungus threatens vulnerable patients—urgent action, early detection, and coordinated efforts are key to limiting its impact.

#InfectionControl #PublicHealth

Dr Diamantis Plachouras - Drug-resistant C. auris spreading in European hospitals The latest survey from the European Centre for Disease Prevention and Control (ECDC), the fourth of its kind, confirms that Candidozyma auris (formerly Candida auris) continues to spread quickly acros

#Multimedia

Listen to a short summary of the survey on C. auris by #ECDC's expert - Dr Diamantis Plachouras:

soundcloud.com/ecdc_eu/in-t...
#ForMedia #SoundBite #CandidaAuris #CandidozymaAuris

Candidozyma auris: Darum warnen Experten vor dem Krankenhaus-Pilz Experten warnen vor dem Hefepilz Candidozyma auris. Er ist hochansteckend, gegen vieles schon resistent - und hat nun deutsche Kliniken erreicht.

#CandidaAuris
#Hefepilze
www.zdfheute.de/panorama/can...

#Medsky🧪#IDsky #microsky #publichealth @ecdc.europa.eu #Candidozymaauris ( #Candidaauris) poses a significant risk to patients in healthcare facilities across 🇪🇺. C.auris can cause severe infections in critically ill patients & resistant to several #antifungal agents,

Fungo killer negli ospedali europei, l'alert Ecdc: Italia fra Paesi più colpiti (Adnkronos) - E' "una seria minaccia per i pazienti e i sistemi sanitari" e si sta "diffondendo rapidamente" negli ospedali europei. Il fungo farmacoresistente Candidozyma auris (già noto come Candida auris), in 10 anni, tra il 2013 e ...

Fungo killer negli ospedali europei, l'alert Ecdc: Italia fra Paesi più colpiti ... LEGGI TUTTO #fungo #CandidaAuris #salute #ospedali #sanità

Krankenhauspilz Candidozyma auris breitet sich aus Die Fälle von Infektionen mit dem Krankenhauspilz Candidozyma auris haben in Europa drastisch zugenommen.

Krankenhauspilz Candidozyma auris breitet sich aus #Krankenhauspilz #Candidaauris #Resistenz

Drug-resistant fungus Candidozyma auris confirmed to spread rapidly in European hospitals: ECDC calls for urgent action The latest survey from ECDC, the fourth of its kind, confirms that Candidozyma auris (formerly Candida auris) continues to spread quickly across European hospitals.

#JustPublished!
Drug-resistant fungus #CandidozymaAuris is spreading rapidly in European hospitals. #ECDC calls for urgent action.

📈 Cases are rising, outbreaks are larger, and several countries now report local transmission.

Press release: bit.ly/46uR1iK
#CandidaAuris #HAI #IDsky #EpiSky #AMR

CDC reports more cases of drug-resistant Candida auris spreading in healthcare facilities. PraediAlert provides instant data and insights to contain outbreaks, protecting patients. thehill.com/homenews... #HealthcareIT #InfectionControl #PatientSafety #CandidaAuris #PraediAlert #DataDriven

Candida auris cases nearly triple as deadly fungus spreads to new states The number of Candida auris infections reported to the Centers of Disease Control and Prevention this year has nearly tripled in the past three and a half months as health care providers struggle to contain the the drug-resistant and deadly fungus.

WHNT 19Alabama News Beacon #CandidaAuris #HealthCare #InfectionControl

Characterizing C auris Progression from Colonization to Infection CDC found 6.9% of those testing positive for Candida auris colonization on skin develop invasive infection, and calls for better surveillance and prevention.

#CDC found 6.9% of those testing positive for #Candidaauris colonization on skin develop invasive infection, and calls for better surveillance and prevention. #PraediAlert provides a feature for surveillance of #Cauris

www.contagionlive.com/view/charact...

#CandidaAuris #DACH-Region #Multiresistenz ggü. #Antimykotika

⬇️❗❗❗

Candida auris Infection Market Forecasted to Soar to USD 2.51 Billion by 2034, Driven by 7.84 Percent CAGR The global Candida auris infection market is on a dramatic upward trajectory with projections estimating growth from USD 1 27 billion in 2025 to USD 2 51 billion by 2034 marking a compound annual grow...

Candida Auris Infection Market 🦠⚠️
#CandidaAuris infection market to hit $2.51B — tackling emerging fungal threats 🧪
#InfectiousDiseases #FungalInfections #Diagnostics

www.openpr.com/news/4105007...

How to interpret MICs of amphotericin B, echinocandins and flucytosine against Candida auris (Candidozyma auris) according to the newly established European Committee for Antimicrobial Susceptibility ... The following ECOFFs and breakpoints were established for C auris: amphotericin B: ECOFF: 2 mg/L, S: ≤0.001 mg/L, R: >2 mg/L; implying that the entire wild-type distribution is susceptible, increased ...

🦠 New EUCAST breakpoints for Candida auris (Candidozyma auris)! Learn how to interpret MICs for amphotericin B, echinocandins & flucytosine based on robust multicenter data. A must-read for clinical labs.
🔗 pubmed.ncbi.nlm.nih.gov/40651666/
#CandidaAuris #EUCAST #AntifungalResistance